ADC Therapeutics SA Income (Loss) from Continuing Operations before Income Taxes, Domestic
ADC Therapeutics SA (ADCT) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$57.95 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-10
- ADC Therapeutics SA income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$57.95M.
- ADC Therapeutics SA income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$44.72M.
- ADC Therapeutics SA income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$7.89M, a 164.62% decline from fiscal 2022.
- ADC Therapeutics SA income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $12.21M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$57.95M 10-K · filed 2026-03-10 |
| 2024-12-31 | -$44.72M 10-K · filed 2026-03-10 |
| 2023-12-31 | -$7.89M 10-K · filed 2025-03-27 |
| 2022-12-31 | $12.21M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |